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Propranolol inhibits growth of hemangioma-initiating cells
but does not induce apoptosis
Jina J.Y. Kum1 and Zia A. Khan1,2
Background: Infantile hemangioma (IH) is the most common tumor of infancy. The first-line therapy for IH is propranolol, a nonselective β-adrenergic receptor antagonist. However,
mechanisms for the therapeutic effect of propranolol and
regrowth of IH following cessation of treatment in some cases
are not clear. We have recently shown that IH arises from multipotent stem cells. Whether IH stem cells are responsive to propranolol and are selectively targeted is unknown, and this is
the focus of this study.
Methods: IH stem cells were exposed to propranolol and
were assayed for cellular and molecular alterations. We used
endothelial cells (ECs) as controls and bone marrow–derived
mesenchymal progenitor cells (bm-MPCs) as normal stem/
progenitor counterparts to determine selectivity.
Results: Our results show that propranolol significantly
reduced IH stem cell growth but failed to induce caspase-3
activation. Normal bm-MPCs and mature ECs showed maintained or increased caspase-3 activation and significantly
reduced cyclin-D1 levels. We further show that IH stem cells
may escape apoptosis by inducing antiapoptotic pathways.
Conclusion: This study reveals that propranolol does not
induce apoptosis in IH stem cells, which is in contrast with
the result for ECs. Escape from apoptosis in IH stem cells may
involve induction of antiapoptotic pathways.

I

nfantile hemangioma (IH) is a benign vascular tumor affecting 1 out of 100 newborns (1,2). IH undergoes three developmental phases: a proliferative phase, where the tumor grows
rapidly and comprises undifferentiated cells during the first
year of life; an involuting phase, where tumor growth slows
and vessels become prominent; and an involuted phase, where
fibrofatty tissue replaces much of the tumor mass (3). A unique
feature only seen in IH is that the tumor follows this natural
course and spontaneously regresses. Hence, most IHs pose no
serious threat or complications to the infant; however, in problematic cases that interfere with health and normal function
due to the size or location of the tumor, patients may require
immediate treatment (4). For example, obstructive IH in
organs such as the eyes or the airway require immediate attention because the tumor may inhibit normal development and
function of the organ and impair the infant permanently (3,5).

Current treatments for IH include surgery when necessary
and use of corticosteroids, despite the severe side effects when
taken for extended periods at high doses. Recently, propranolol was discovered to be an effective treatment for IH (6), with
higher efficacy and minimal side effects when compared with
corticosteroids (7). Propranolol is a nonselective β-adrenergic
receptor antagonist that has been widely used for complications such as angina pectoris, myocardial infarction, and
hypertension. Although the mechanism of therapeutic effect
of propranolol is unknown, theories suggest vasoconstriction,
endothelial cell (EC) apoptosis, and inhibition of angiogenesis
by modulating vascular endothelial growth factors (8–11). In
fact, a number of recent studies have shown that propranolol
treatment of both normal ECs and ECs derived from IH specimens causes activation of caspase-3 (12,13). Caspase-3 is an
important regulator of cellular apoptosis and is recognized as
an indispensable death protease for apoptotic chromatin condensation and DNA fragmentation in all cell types examined
(reviewed in ref. (14)). In addition to inducing apoptosis, propranolol also decreases the expression of various cyclins in
ECs, thus disrupting cell cycle progression and growth (12).
A puzzling finding from a few propranolol treatment studies
in patients is that some IHs regrow on cessation of propranolol
treatment (15–17). This has been attributed to early treatment
withdrawal and/or a long proliferating phase of IH. Previously,
we have shown that IH arises from multipotent stem cells
(termed hemSCs for hemangioma-derived stem cells)(18).
HemSCs, isolated based on expression of stem cell antigen
CD133, form glucose transporter-1–positive microvessels in
immunodeficient mice. These glucose transporter-1–positive
vessels are later replaced by human adipocytes that mimic the
natural stages of human IH. Interestingly, IH-derived ECs are
unable to produce microvessels (18). This suggests that hemSCs may be responsible for the recurrence of IH on cessation of
propranolol treatment, possibly owing to the nonresponsiveness of hemSCs to propranolol. In this study, we have explored
this possibility by treating primary hemSCs with propranolol
to determine whether propranolol induces caspase-3 activation and apoptosis, as has been shown for vascular ECs. We
have also studied bone marrow–derived mesenchymal progenitor cells (bm-MPCs) as normal counterparts of hemSCs
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to determine whether changes (if any) observed in hemSCs are
specific or whether the response depends on the stem/progenitor phenotype. In addition, we investigated possible signaling
pathways involved on propranolol treatment.

(Figure 2a). No significant differences were found in the level
of β2- or β3-adrenergic receptors between ECs, hemSCs, and
bm-MPCs.

RESULTS

Our next objective was to determine the effect of propranolol on the growth of hemSCs. We cultured the cells with 25,
50, and 100 µmol/l propranolol and assayed for cell number
at both 24 and 72 h. We chose these concentrations based
on previous studies that have observed significant differences in IH ECs (9,12). Furthermore, propranolol has been
shown to have immediate effects in inhibiting cell viability at
24 h (13). Interestingly, no significant changes in cell number
were observed in any cell type at 24 h (data not shown). At
72 h, however, bm-MPCs and HDMECs showed significant

Figure 1. CD133-positive cells line hemangioma vessels. Proliferating
hemangioma specimens were double labeled for CD31 (endothelial cell
marker; red) and CD133 (stem cell antigen; green). 4′,6-Diamidino-2phenylindole (blue) was used as counterstain. Staining illustrates complete colocalization of CD133 and CD31 in both proliferating hemangioma
specimens (images were taken at magnification of ×20 ; insets illustrate
high magnification; bar = 200 µm).
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We first assayed for β-adrenergic receptor expression in hemSCs and compared the levels with those in mature ECs. Our
results show that hemSCs express both β2- and β3-adrenergic
receptors (Figure 2a). β1-adrenergic receptor mRNA levels,
although detectable, were significantly lower. Interestingly,
we found that bm-MPCs share β-adrenergic receptor profile
with hemSCs. Mature ECs (human microvascular ECs; human
dermal microvascular ECs (HDMECs)) on the other hand
exhibited higher level of β1-adrenergic receptor expression
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β2 and β3 Are the Predominant β-Adrenergic Receptors in IH
Stem Cells

a
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A number of studies have investigated the effect of propranolol on IH-derived ECs to offer insight into the mechanisms
of therapeutic effect of propranolol (12,13,19). These studies
show that propranolol causes apoptosis in IH ECs by activating
caspase-3 and blocks other cellular activities including migration and tubule formation (12,13). This effect of propranolol
is also exhibited by normal ECs (9,12). We have shown that
IH arises from multipotent stem cells (18). CD133-positive
cells from human IH produce hemangioma lesions in mice.
Interestingly, IH-derived ECs (exhibiting mature endothelial
phenotype as assessed by EC markers) fail to produce glucose
transporter-1–positive microvessels (18). This suggests that
the cell of interest, at least in proliferating-phase IH when
treatments are required, is the hemSC. Therefore, we performed immunostaining for CD133 to probe for the number of microvessels that are lined by CD133-expressing cells.
Results from two proliferating IH specimens show that all
microvessels within IH tissues are immunoreactive to CD133
(Figure 1). This suggested that for understanding the effect of
propranolol, CD133-positive hemSCs are essential.

Cell number (× 10,000)

Atypical Phenotype of IH Endothelium

Propranolol Inhibits IH Stem Cell Growth

HDMEC

Figure 2. Propranolol reduces hemangioma-derived stem cell (hemSC)
growth. (a) mRNA levels of β-adrenergic receptors in CD133-positive
hemSCs, normal bone marrow–derived mesenchymal progenitor cells
(bm-MPCs), and human dermal microvascular endothelial cells (HDMECs)
were determined by real-time quantitative reverse-transcriptase PCR (data
normalized to β-actin; *P < 0.05 compared with β1-adrenergic receptor
mRNA levels in hemSCs and bm-MPCs; †P < 0.05 compared with β2- and
β3-adrenergic receptor mRNA levels). RNA was isolated from cells cultured
in Endothelial Basal Media-2 (EBM2) under identical conditions. The
specificity of the amplification was determined by melting curve analysis
(data not shown). (b) Total live cell number after 72 h of treatment with different concentrations of propranolol. Propranolol treatment at 100 µmol/l
showed reduced number of cells compared with control in all cell types
tested (*P < 0.05 compared with respective control).
Copyright © 2014 International Pediatric Research Foundation, Inc.
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Reduced Cell Number Following Propranolol Treatment Is Not
Due to Apoptosis in IH Stem Cells

Propranolol Induces Antiapoptotic Pathways in hemSCs

To understand the possible mechanism by which propranolol
induces apoptosis in ECs but not in hemSCs, we used quantitative reverse-transcriptase PCR (RT-PCR) to obtain the profiles of genes important in the central mechanisms of cellular
death. We used Human Cell Death Pathway Finder PCR Array
(Qiagen, Mississauga, ON; see Methods section for details),
which comprises 84 key genes important for cell survival and
apoptosis. HemSCs, bm-MPCs, and HDMECs were cultured
in normal growth media or in media containing different
concentrations of propranolol for 72 h. Using this PCR-based
Copyright © 2014 International Pediatric Research Foundation, Inc.

*

bm-MPC

100 µmol/l

0 µmol/l

100 µmol/l

0 µmol/l

100 µmol/l

0 µmol/l

HemSC

b

HDMEC

2

1

*

*

HemSC

bm-MPC

100 µmol/l

0 µmol/l

0 µmol/l

100 µmol/l

*

0
100 µmol/l

We examined the effect of propranolol on cyclin-D1 levels.
Cyclin-D1 is a key regulator in the progression from G1/S
phase and has recently been shown to be maintained in the
G2 phase (20). Recent studies have shown that propranolol
reduces cyclin-D1 in a time-dependent manner in ECs (9).
Surprised by previous experimental findings, we wanted to
determine whether propranolol reduces cyclin-D1 in hemSCs.
Our results do show significantly reduced cyclin-D1 in hemSCs on propranolol treatment (Figure 3b). Similarly, cyclinD1 levels in bm-MPCs and HDMECs were also significantly
reduced (Figure 3b). The greatest change in cyclin-D1 was
seen in bm-MPCs, which may explain the reduced cell number seen earlier. These results suggest that propranolol inhibits
cell cycle progression in all cell types by decreasing the level of
cyclin-D1.
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Because the cell number decreased significantly for all cell
types when cultured in 100 µmol/l propranolol (at 72 h), we
examined whether this was due to apoptosis. Therefore, cells
treated with propranolol were assayed for active caspase-3.
Caspase-3 is the most frequently activated death protease and
plays a role in inducing EC apoptosis on propranolol treatment
(12,13). Unexpectedly, hemSCs treated with 100 µmol/l propranolol showed a significant reduction in the level of active
caspase-3. This suggested that in hemSCs, the reduction in cell
number might be due to inhibited cell growth and not apoptosis. bm-MPCs did not show a significant difference on propranolol treatment as caspase-3 levels remained unchanged
(Figure 3a). On the other side of the spectrum, propranololtreated HDMECs showed a significant increase in the level
of activated caspase-3 as expected. These data demonstrate
that propranolol treatment induces apoptosis in HDMECs,
whereas the decrease in cell number in hemSCs—and possibly
bm-MPCs—is mediated by a reduction in cell growth.

2
Active caspase-3 (fold change)

reductions in cell number at all concentrations of propranolol
when compared with control (Figure 2b). In contrast, a proliferative effect was observed when hemSCs were treated with 25
µmol/l propranolol, and a reduction in total live cell number
was observed with 100 µmol/l propranolol (Figure 2b).

HDMEC

Figure 3. Propranolol reduces active caspase-3 level in hemangiomaderived stem cells (hemSCs). Levels of (a) activated caspase-3 and (b)
cyclin-D1 in hemSCs, bone marrow–derived mesenchymal progenitor cells
(bm-MPCs), and human dermal microvascular endothelial cells (HDMECs)
following 100 µmol/l propranolol treatment for 72 h (*P < 0.05 compared
with respective 0 µmol/l treatment/control).

array, we found that propranolol significantly induces various antiapoptotic pathways in hemSCs and normal bm-MPCs
(Figure 4a). These included Akt (also known as protein kinase
B; induced 31.2× in hemSCs and 7.58× in bm-MPCs), Bcl2
(induced 295.9× in hemSCs and 143.2× in bm-MPCs)/Bcl2A
(induced 23.47× in hemSCs and 10.97× in bm-MPCs), and
insulin-like growth factor receptor-1 (IGFR-1; induced 53.68×
in hemSCs and 9.29× in bm-MPCs). In contrast, we did not
observe any alterations of these antiapoptotic pathways in
HDMECs (Figure 4a).
TNF-α, but Not IFN-γ, Reduced Cell Growth in IH Stem Cells

In addition to inducing antiapoptotic pathways, we observed
that propranolol treatment significantly increased tumor
necrosis factor (TNF) pathway members and interferon-γ
(IFN-γ) in hemSCs and, to a lesser degree, in bm-MPCs
(Figure 4b,c). This led us to question whether TNF or IFN
signaling mediates the changes that we have observed in hemSCs on propranolol challenge. We first determined the effect
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of exogenous TNF-α treatment on hemSCs. Interestingly,
there was a significant cell number reduction in hemSCs on
exposure to 50 and 100 ng/ml TNF-α (Figure 5a). We then
investigated the effect of TNF-α on activated caspase-3 level in
hemSCs. If propranolol is acting through the TNF-α pathway,
then we would expect no increase in caspase-3 activity. Indeed,
our results show that TNF-α-treated hemSCs did not show
changed active caspase-3 level when compared with control
(Figure 5b). We then tested the possible involvement of IFNγ by exposing hemSCs and bm-MPCs to exogenous IFN-γ.
Our studies show no significant effect on hemSC or bm-MPC
growth at 24 or 72 h (Figure 5c,d). This suggests that TNF-α,
but not IFN-γ, has an antiproliferative effect in vitro and may
be involved in propranolol’s action.

Figure 4. Propranolol induces antiapoptotic signaling pathways in
hemangioma-derived stem cells (hemSCs). Propranolol induced the
expression of (a) antiapoptotic genes, (b) tumor necrosis factor (TNF)
superfamily signaling pathway, and (c) interferon-γ (IFN-γ) in hemSCs
and bone marrow–derived mesenchymal progenitor cells (bm-MPCs)
but not in human dermal microvascular endothelial cells (HDMECs)
(mRNA levels were measured using RT2 Cell Death Pathway Finder
(Qiagen, Mississauga, ON) and normalized to β-actin and glyceraldehyde 3-phosphate dehydrogenase levels; red dashed lines in panels a
and b highlight 100 µmol/l propranolol groups; graphs shown in a–c
are representative of multiple PCR arrays).
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While our studies were underway, a report showed that presence
of propranolol in adipogenic differentiation media increased the
differentiation level in hemSCs compared with the differentiation level in cells grown in adipogenic media alone (21). Higher
levels of CCAAT-enhancer-binding protein β (C/EBPβ) and δ
were found at day 4. Interestingly, when the cells were maintained in the differentiation media supplemented with propranolol for 7 d, significant cell death was observed. This is in
contrast with our observations in normal growth media where
a significant reduction in cell number is evident without apoptosis. Therefore, we explored the possibility that this enhanced
adipogenic differentiation with propranolol is mediated through
cell growth regulation. To test this idea, we treated hemSCs
with mitomycin C to inhibit proliferation and tested for C/EBP
expression. Our results show that C/EBPα was significantly
higher when mitomycin C–treated hemSCs were exposed to
adipogenic differentiation media for 4 d (Figure 6a). No change
was observed in peroxisome proliferator–activated receptor-γ
(PPARγ2) levels. C/EBPα is a critical transcription factor in
adipogenesis and enhanced levels suggest that inhibition of cell
proliferation increases the differentiation capacity of hemSCs,
and this may be the mechanism underlying propranolol’s effect.
We then assayed for β-adrenergic receptor expression and show
here that adipogenesis is associated with significantly higher levels of all three adrenergic receptors (Figure 6b). Therefore, cell
death in adipogenic media supplemented with propranolol (21)
might be due to increased expression of β-adrenergic receptors,
which accompanies hemSC differentiation.
DISCUSSION
Propranolol is now widely used for treating IH; however, the
mechanism of its therapeutic effect is still unknown. In addition, some IHs regrow after stoppage of propranolol treatment
(15–17). In this study, we have demonstrated that propranolol
does not induce apoptosis in hemSCs, cells responsible for IH
initiation, as seen in mature/differentiated ECs. This suggests
that the direct effect of propranolol in IHs may be through
both modulation of mature ECs and angiogenesis (Figure 7a).

Copyright © 2014 International Pediatric Research Foundation, Inc.
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Figure 5. Tumor necrosis factor (TNF) activation leads to reduced cell growth in hemSCs. TNF-α treatment significantly reduced cell number (a) in hemSCs after 72 h but did not change (b) activated caspase-3 level (*P < 0.05 compared with control). HemSCs treated with interferon-γ (IFN-γ) showed no
significant change in cell number after (c) 24 or (d) 72 h. bm-MPCs, bone marrow–derived mesenchymal progenitor cells; hemSCs, hemangioma-derived
stem cells.

The mechanism by which hemSCs and possibly normal progenitor cells (modeled here by bm-MPCs) escape apoptosis may
include induction of antiapoptotic pathways. We found Akt,
Bcl2/Bcl2A, and IGFR-1 to be significantly induced in hemSCs and bm-MPCs. Akt induction is of particular importance
here as this prosurvival kinase counteracts caspase-3 activity
(22–24). Bcl2 downregulation has been shown to increase caspase-3 in breast cancer cells (25). Furthermore, Bcl2A mediates the antiapoptotic effects of fibroblast growth factor in
chondrogenic progenitor-like cell lines (26). Therefore, these
pathways may be involved in reducing/counteracting caspase-3 activity in hemSCs but not in mature ECs.
We also examined whether the extrinsic apoptotic pathway
is involved in propranolol-induced growth inhibition. The
extrinsic pathway is primarily mediated by the TNF superfamily. We found that TNF signaling pathway genes (listed in
Figure 4b) are also upregulated in hemSCs and bm-MPCs on
propranolol treatment. Because it is well known that TNF signaling pathways are involved in cell death, these results were
unexpected. However, recent studies show that TNF’s effect
may not be limited to cell apoptosis. TNF-α causes cell cycle
arrest, but not death, in keratinocytes (27), glioblastoma cells
(28), and melanoma cell lines (29). These findings suggest two
independent antiproliferative mechanisms of TNF signaling.
In hemSCs, TNF signaling may be involved in propranololmediated cell cycle arrest. Indeed, when we treated hemSCs to
exogenous TNF-α, we noted decreased cell growth over 72 h
but no change in caspase-3 activity. Taken together with the
results of antiapoptotic gene induction, we believe propranolol
may reduce hemSC growth by inducing the TNF pathway and
may facilitate the escape from caspase-3 activation and apoptosis by TNF-independent induction of antiapoptotic genes.
Another interesting finding of this study is that hemSCs
predominantly express β2- and β3-adrenergic receptors. β1
receptor levels are almost 10-fold lower. Vascular ECs, on
the other hand, express significantly high levels of β1 receptor compared with β2/3. These findings suggest that the
Copyright © 2014 International Pediatric Research Foundation, Inc.

differential effect of propranolol in hemSCs and ECs may be
due to the distinct roles of the β-adrenergic receptor subtypes.
Communal et al. (30) have shown that activation of β1 receptors on cardiac myocytes induces apoptosis, whereas activation of β2-adrenergic receptor opposes cell death. Although
this study involved activation of β-adrenergic receptor and
not antagonism, the concept of a distinct, receptor subtype–
specific role is pertinent here. Moreover, Panjala et al. (31)
have demonstrated that β1-adrenergic receptor knockout
mice exhibit increased formation of degenerate capillaries in
the retina. These are interesting findings because retinal ECs
express β1-, but not β2-, adrenergic receptors (32). Also associated with acellular capillaries in the retina in knockout mice
were increased level of cleaved caspase-3. Based on our data,
we suggest that antagonizing β1 receptor in IH cells is associated with cell death, whereas β2 is involved with cell cycle
regulation (Figure 7b). We know that hemSCs predominantly
express β2 and β3 receptors and show almost 10-fold lower β1
levels. bm-MPCs showed a similar response to propranolol in
terms of cellular activity and molecular alterations and share
the β-adrenergic receptor profile of hemSCs.
Wong et al. (21) have recently shown that propranolol
enhances adipogenesis in hemSCs. Specifically, presence of
propranolol in adipogenic media initially caused differentiation of hemSCs but significant cell death at day 7 (21), which is
the typical in vitro time for full functional adipocyte differentiation. We reasoned that the initial effect of propranolol might
be mediated through cell cycle disruption. To test this possibility, we treated hemSCs with mitomycin C before exposing
the cells to adipogenic differentiation media. We noted that
mitomycin C–treated cells had significantly higher levels of
C/EBPα induction, suggesting that enhanced adipogenesis
in hemSCs may be related to a change in the differentiation
timeline (reduced growth and earlier differentiation). We also
tested whether adipogenesis itself alters β-adrenergic receptor
expression in hemSCs, thereby making cells more sensitive to
propranolol and possibly explaining cell death observed in the
Volume 75 | Number 3 | March 2014      Pediatric Research 
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Figure 6. Growth inhibition enhances adipogenesis. Effect of mitomycin
C treatment on adipogenic differentiation (a) in hemSCs at day 4 (Adipo,
adipogenic media; MitoC, mitomycin C; *P < 0.05 compared with control
media; †P < 0.05 compared with adipogenic differentiation media without
mitomycin C treatment). (b) Induction of β-adrenergic receptors following
adipogenic differentiation in hemSCs at day 7 (Adipo, adipogenic media;
*P < 0.05 compared with control media).

previous study (21). Indeed, differentiation of hemSCs significantly increased the expression of all β-adrenergic receptor
subtypes, including β1. Therefore, cell death seen in adipocytes
may be associated with the increase in β1 receptor expression
(29.47-fold increase, as reported in our study). Increased level
of β2 receptors in adipocytes may further enhance the inhibitory process by regulating cell cycle progression.
Our study represents an important step toward understanding the mechanism of propranolol action. A number of
pressing questions remain. For example, is propranolol selective to IH vessels? Based on recent findings in ECs (normal
vs. IH-derived) and our own findings in hemSCs, this seems
unlikely. Alternatively, the effectiveness of propranolol in IHs
may be a function of increased levels that are sustained in the
capillary mass of IHs. These studies are under way in our laboratory, and the findings may enhance our understanding of the
mechanism of therapeutic action of propranolol and may provide more effective treatment options.
386 Pediatric Research      Volume 75 | Number 3 | March 2014

Figure 7. Proposed mechanism of therapeutic effect of propranolol.
Schematic representation illustrating the proposed mechanism of
propranolol action on hemSCs and mature endothelial cells (ECs). (a)
Schematic diagram illustrating the penetrance of apoptotic effect of
propranolol in hemangioma regression. (b) Propranolol leads to cell
apoptosis in endothelial cells and other mature cell types, including
adipocytes, through alteration of β1-adrenergic receptor signaling.
Engagement of β2- (and possibly β3-) adrenergic receptors leads to cell
cycle arrest and growth inhibition.

METHODS

IH Specimens and Immunostaining
We obtained paraffin-embedded IH specimens from the Department
of Pathology Archives at the London Health Sciences Centre (London,
Ontario, Canada). The proliferating phase was confirmed by histological analysis. Tissue sections were deparaffinized, hydrated, and subjected to antigen retrieval using Tris/EDTA buffer (10 mmol/l Trizma
base, 1 mmol/l EDTA, 0.05% Tween-20, pH 9.0) in 2100 Retriever
(Electron Microscopy Sciences, Hatfield, PA). To perform double
staining, we incubated slides with mouse anti-human CD31 (1:50;
M0823, Dako, Canada, Mississauga, ON) and rabbit anti-human
CD133 antibody (1:100; ab19898, Abcam, Cambridge, MA) for 1 h
at room temperature. Fluorescein- or Texas Red–conjugated secondary antibodies (Vector Laboratories, Burlington, ON) were used for
detection. Slides were counterstained with 4′,6-diamidino-2-phenylindole (Vector Laboratories). Images were taken using an Olympus
BX-51 microscope (Olympus Canada, Richmond Hill, ON) equipped
with a Spot Pursuit digital camera (SPOT Imaging Solutions, Sterling
Heights, MI).
IH Cell Isolation and Culture
Proliferating IH-derived CD133+ cells (hemSCs) were kindly provided by Dr. Joyce Bischoff (Children’s Hospital Boston, Boston,
MA). We have previously shown full characterization of hemSCs
and culture conditions (18). Freshly isolated bm-MPCs (isolated
from bone marrow–derived mononuclear preparations; 2M-125B,
Lonza, Walkersville, MD) were used as normal stem/progenitor controls. Neonatal HDMECs (CC-2516, Lonza) were also used as controls. Previous studies have compared normal ECs with IH-derived
mature ECs and have shown striking similarity in propranolol
response (9,12,13). All cells were cultured on fibronectin-coated (FN;
Copyright © 2014 International Pediatric Research Foundation, Inc.
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1 µg/cm2, FC010-10, Millipore, Temecula, CA) plates in Endothelial
Basal Media-2 (Lonza) supplemented with 20% fetal bovine serum
(Lonza) and SingleQuots (CC-4176, Lonza) and 1× antibiotic antimycotic media (Penicillin-Streptomycin-Fungizone, PSF; Life
Technologies, Burlington, ON). All cells were cultured under identical conditions, and experiments were performed with a minimum
of two biological replicates (different IH cell preparations) and three
technical replicates. All studies were conducted following approval
by the Research Ethics Board at The University of Western Ontario,
London, Ontario, Canada.
Cell Growth Assay
To determine the effect of propranolol on cell growth, we plated each
cell type at 5,000 cell/cm2 in complete endothelial growth medium
(described above). After 24 h, the medium was removed and cells
were exposed to 25, 50, or 100 µmol/l (R)-(+)-propranolol hydrochloride (Propranolol; 0624, R&D Systems, Minneapolis, MN) in fresh
media. Total number of live cells was determined at 24 or 72 h using
Scepter 2.0 Automated Cell Counter (Millipore) with appropriate histogram gating setup (33,34). For some experiments, hemSCs and bmMPCs were treated with IFN-γ (285-IF-100, R&D systems) or TNF-α
(210-TA-010/CF, R&D systems) for up to 72 h.
RNA Isolation, mRNA Profiling, and Quantitative RT-PCR
RNA was isolated using RNeasy Micro Plus Kit (Qiagen). Total
amount of RNA was measured using Qubit RNA Broad Range Assay
in a Qubit Fluorometer (Life Technologies). cDNA was then synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA). We performed gene expression analyses using using
RT2 Human Cell Death Pathway Finder PCR arrays (PAHS-212Z;
Qiagen) in Bio-Rad CFX Connect (Bio-Rad). Data were analyzed by
CFX Manager Software using normalized (ΔΔCT) method with two
housekeeping genes (β-actin and glyceraldehyde 3-phosphate dehydrogenase were both used for normalization after empirically determining the expression for stability in our treatment groups).
Levels of β-adrenergic receptor and adipogenesis-specific gene
expression were also assessed by quantitative RT-PCR. Reactions consisted of 10 µl SsoFast Evagreen (1725200, Bio-Rad), 2 µl of both forward and reverse primers (at a 10 µmol/l concentration), 2 µl cDNA,
and 6 µl of H2O. Adipogenesis was assessed by C/EBPα (QT00203357,
Qiagen) and PPARγ2 levels (sequence shown in ref. (35)). Expression
levels of β1- (QT00204309, Qiagen), β2- (QT00200011, Qiagen), and
β3-adrenergic receptors (QT00200004, Qiagen) were measured similarly. Target gene mRNA data were normalized to β-actin expression
(QT01680476, Qiagen). All reactions were performed for 40 cycles
using the following temperature profiles: 95 °C for 2 min (initial denaturation); and 55 °C for 12 s (annealing and extension). Data were
analyzed using relative quantity (ΔCT).
Caspase-3 and Cyclin-D1 Measurements
Total proteins from the cultured cells were extracted using Cell
Extraction Buffer (Life Technologies) with complete protease inhibitor
cocktail (Roche Diagnostics, Laval, Quebec). Proteins were measured
by BCA Protein Assay Reagent (Pierce BCA Protein Assay Kit, Thermo
Scientific, Rockford, IL), and equal amounts were used for active caspase-3 and cyclin-D1 measurements. To measure activated caspase-3,
caspase-3 (active) Human ELISA kit (Life Technologies) was used.
Data were collected using Thermo Scientific Multiskan FC Microplate
Photometer (Thermo Scientific), measuring absorbance at 450 nm.
Cyclin-D1 level was measured similarly using PathScan Total Cyclin-D1
Sandwich ELISA kit (Cell Signaling Technology, Danvers, MA).
Adipogenic Differentiation
To induce adipogenic differentiation, hemSCs were seeded at a density of 40,000 cells/cm2 in StemPro Adipogenesis differentiation
medium (Adipo media; Life Technologies). Control medium consisted of Dulbecco’s Modified Eagle Medium supplemented with
10% fetal bovine serum. Medium was changed every other day. RNA
was isolated from cells after 7 d to perform quantitative RT-PCR for
β-adrenergic receptor expression. To determine whether cell growth/
proliferation may alter adipogenesis, we pretreated hemSCs with
10 μg/ml mitomycin C (MitoC; Sigma Aldrich, Oakville, ON) for 2 h.
Copyright © 2014 International Pediatric Research Foundation, Inc.
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Cells were then washed, resuspended, and plated at 40,000 cells/cm2
in adipogenesis media. RNA was isolated at day 4 to assay for C/EBPα
and PPARγ2 levels (transcription factors essential for adipogenic differentiation) (33–35).
Statistical Analysis
The data were expressed as mean ± SEM. Where appropriate, corrected ANOVA or two-tailed Student’s unpaired t tests were performed. P values <0.05 were considered statistically significant.
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